Stock SIGA SIGA TECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company SIGA Technologies, Inc.

Equities

SIGA

US8269171067

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-16 pm EDT 		After market 04:19:37 pm
8.93 USD +0.56% Intraday chart for SIGA Technologies, Inc. 8.87 -0.67%
Apr. 01 SIGA Technologies to Drive International Promotion for Oral TPOXX in Amended Deal With Meridian Medical MT
Apr. 01 SIGA Technologies, Inc. Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX CI

Business Summary

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.

Number of employees: 45

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
111 100.0 % 140 100.0 % +26.31%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
84.8 %
121 90.3 % 119 84.8 % -1.66%
Europe, Middle East and Africa (EMEA)
14.5 %
13 9.7 % 20 14.5 % +55.99%
Asia-Pacific
0.7 %
-- 1 0.7 % -

Managers

Managers TitleAgeSince
Diem Nguyen CEO
 Chief Executive Officer 52 Jan. 26
Daniel Luckshire DFI
 Director of Finance/CFO 53 11-02-09
Tove C. Bolken COO
 Chief Operating Officer - 97-12-31
Herb Vloedman CTO
 Chief Tech/Sci/R&D Officer - 08-12-31
Jay Kumar Varma CTO
 Chief Tech/Sci/R&D Officer 52 22-11-09
Dennis Hruby CTO
 Chief Tech/Sci/R&D Officer 72 95-12-31

Members of the board

Members of the board TitleAgeSince
Joseph Marshall BRD
 Director/Board Member 71 09-03-10
Jaymie A. Durnan BRD
 Director/Board Member 70 20-06-15
Harold E. Ford BRD
 Director/Board Member 53 22-11-09
Julian Nemirovsky BRD
 Director/Board Member 40 20-12-09
Gary Nabel BRD
 Director/Board Member 70 21-06-14
Jay Kumar Varma CTO
 Chief Tech/Sci/R&D Officer 52 22-11-09
Diem Nguyen CEO
 Chief Executive Officer 52 Jan. 26
Holly L. Phillips BRD
 Director/Board Member 53 21-06-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 71,091,616 64,411,601 ( 90.60 %) 0 90.60 %

Shareholders

NameEquities%Valuation
MacAndrews & Forbes Holdings, Inc.
33.98 %
24,156,358 33.98 % 207 M $
John Latane Iv Lewis
7.415 %
5,271,365 7.415 % 45 M $
BlackRock Advisors LLC
4.663 %
3,315,333 4.663 % 28 M $
Federated MDTA LLC
4.529 %
3,219,848 4.529 % 28 M $
First Wilshire Securities Management, Inc.
3.323 %
2,362,107 3.323 % 20 M $
Van Lanschot Kempen Investment Management NV
3.199 %
2,274,359 3.199 % 19 M $
Vanguard Fiduciary Trust Co.
3.154 %
2,242,097 3.154 % 19 M $
AltraVue Capital LLC
2.874 %
2,043,196 2.874 % 17 M $
Royce & Associates LP
2.470 %
1,756,311 2.470 % 15 M $
Dimensional Fund Advisors LP
2.389 %
1,698,154 2.389 % 15 M $

Company contact information

SIGA Technologies, Inc.

31 East 62nd Street

10065, New York

+

http://www.siga.com
address SIGA Technologies, Inc.(SIGA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for SIGA Technologies, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SIGA TECHNOLOGIES, INC. Stock SIGA Technologies, Inc.
+59.46% 631M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+28.10% 676B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.27% 559B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.84% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.71% 320B
ABBVIE INC. Stock AbbVie Inc.
+4.88% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.62% 213B
NOVARTIS AG Stock Novartis AG
+0.15% 207B
ROCHE HOLDING AG Stock Roche Holding AG
-9.41% 199B
AMGEN INC. Stock Amgen Inc.
-7.77% 142B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SIGA Stock
  4. Company SIGA Technologies, Inc.